Troponin: the biomarker of choice for the detection of cardiac injury

By L. Babuin, Allan S. Jaffe. Canadian Medical Association Journal, 2005

684 citations recorded by the source corpus.

It has been known for 50 years that transaminase activity increases in patients with acute myocardial infarction. With the development of creatine kinase (CK), biomarkers of cardiac injury began to take a major role in the diagnosis and management of patients with acute cardiovascular disease. In 2000 the European Society of Cardiology and the American College of Cardiology recognized the pivotal role of biomarkers and made elevations in their levels the “cornerstone” of diagnosis of acute myocardial infarction. At that time, they also acknowledged that cardiac troponin I and T had supplanted CK-MB as the analytes of choice for diagnosis. In this review, we discuss the science underlying the use of troponin biomarkers, how to interpret troponin values properly and how to apply these measurements to patients who present with possible cardiovascular disease.

Subfields: Cardiology and Cardiovascular Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/2c14c2af41a5248e1875522ce7ba07cebbb778ab

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Plante
2. Pierre-Luc Mercier
3. K. Ghani
4. D. Bachvarov
5. J. Grégoire
6. B. Têtu
7. M. Bachvarova
8. I. Bairati

Citations in the corpus

• Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer (2011, background): “…different members of the collagen network, which are known to be implicated in cellular morphology, as well as in increased cellular growth andmigration (Babuin and Jaffe, 2005; Bartling et al., 2009; Ichii et al., 2001; Ip et al., 2011; Krudy et al., 1994; Petit et al., 2000; Piehl et al., 2007).”